~~<i id='8993B07ED4'><strike id='8993B07ED4'><tt id='8993B07ED4'><pre id='8993B07ED4'></pre></tt></strike></i>~~

Home» focus» leisure time

leisure time

author：explore 2025-10-01 03:24:30 Page View：79

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Americans' trust in science, scientist continues decline: Report
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

focus

Continuity nursing helped my family in our darkest PICU moments

EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

FDA needs staff influx to meet gene therapy needs, Marks says

FDA'sPeterMarksJIMLOSCALZO/POOL/AFPviaGettyImagesWASHINGTON—TheFoodandDrugAdministrationneedsdozensm

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

The woman behind the Dana Farber

LaurieGlimcher,CEOofDanaFarberCancerInstitute,isthearchitectofthebiggestshakeupinBostonhealthcareind